Three generic drug makers agreed to pay nearly $450 million to resolve civil allegations that they conspired to fix prices for numerous medications, which caused U.S. federal government health care programs and their beneficiaries to overpay for the treatments.
In each instance, the companies — the Sandoz unit at Novartis (NVS), Taro Pharmaceuticals and Apotex — admitted to working with rivals to set prices and supplies, and allocate customers for different medicines between 2013 and 2015, according to the U.S. Department of Justice. The drugs included treatments for high cholesterol, pain, fungal infections, and skin infections, among other maladies.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
